相关实验视频

Updated: Jan 8, 2026

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Published on: August 12, 2014

天母细胞瘤的分子和临床分层:三个不同的融合定义的群体,为风险适应的治疗策略提供信息

Aniello Federico^1,2,3, Felix Schmitt-Hoffner^1,2,3,4, Adriana Fonseca⁵

¹Hopp-Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.

|December 22, 2025

概括

天母细胞瘤,MN1-改变,被重新定义为三个不同的分子组. 一个高风险群体从放射治疗中受益,为这种罕见的脑瘤指导新的风险分层治疗方法.

科学领域:

神经瘤学神经瘤学
分子病理学分子病理学
基因组学就是基因组学.

背景情况:

天母细胞瘤是罕见的儿科和年轻成年人脑瘤,其分子亚型和治疗策略未被定义.
目前的分类缺乏分子细粒度,阻碍了向治疗.

研究的目的:

通过使用综合性分析来分子分类"天体母细胞瘤,MN1-改变".
识别具有不同预后和治疗反应的不同子组.

主要方法:

分析了200名患者的瘤样本,分子概况和临床数据.
使用了DNA甲基化分析,DNA/RNA测序和生存分析.
根据世卫组织的"天母细胞瘤,MN1-改变"标准对瘤进行分类.

主要成果:

根据DNA甲基化和融合基因 (例如,MN1::BEND2,EWSR1::BEND2,MN1::CXXC5) 确定了三个分子组 (A,B,C).
与A组和C组相比,B组 (EWSR1::BEND2合并) 的预后明显较差 (5年PFS14%)
放射治疗改善了无进展生存率,特别是在B组 (危险比率为0.25).

结论:

"天母细胞瘤,MN1-改变"包括三个不同的分子和临床组.
确定了用于风险分层的新型融合基因和潜在生物标志物 (例如14q/16q损失).
建立了适应风险的治疗策略的框架,包括对高风险分子子组的放射治疗.

关键词:

EWSR1::BEND2 提供一个简单的方法.在MN1中被改变了.MN1::BEND2 在线播放 MN1::CXXC5 的意思在天体母细胞瘤.这是基因融合,基因融合.

更多相关视频

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening

Published on: September 5, 2025

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...